» Authors » Gabriella F Kocsis

Gabriella F Kocsis

Explore the profile of Gabriella F Kocsis including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 16
Citations 301
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Pipicz M, Kocsis G, Sarvary-Arantes L, Bencsik P, Varga Z, Ferdinandy P, et al.
Molecules . 2017 Mar; 22(3). PMID: 28282895
Administration of low-dose endotoxin (lipopolysaccharide, LPS) 24 h before a lethal ischemia induces pharmacological late preconditioning. The exact mechanism of this phenomenon is not clear. Here we aimed to investigate...
2.
Kiss K, Csonka C, Paloczi J, Pipis J, Gorbe A, Kocsis G, et al.
Pharmacol Res . 2016 Aug; 113(Pt A):62-70. PMID: 27521836
Erythropoietin (EPO) has been shown to protect the heart against acute myocardial infarction in pre-clinical studies, however, EPO failed to reduce infarct size in clinical trials and showed significant safety...
3.
Manczinger M, Bocsik A, Kocsis G, Voros A, Hegedus Z, Ordogh L, et al.
Biomed Res Int . 2015 Sep; 2015:398045. PMID: 26366412
To better understand the molecular events underlying vulvovaginal candidiasis, we established an in vitro system. Immortalized vaginal epithelial cells were infected with live, yeast form C. albicans and C. albicans...
4.
Pipicz M, Varga Z, Kupai K, Gaspar R, Kocsis G, Csonka C, et al.
Br J Pharmacol . 2015 Apr; 172(14):3472-83. PMID: 25827015
Background And Purpose: Rapid ventricular pacing (RVP) applied before an index ischaemia has anti-ischaemic effects. Here, we investigated whether RVP applied after index ischaemia attenuates reperfusion injury and whether peroxynitrite,...
5.
Varga Z, Zvara A, Farago N, Kocsis G, Pipicz M, Gaspar R, et al.
Am J Physiol Heart Circ Physiol . 2014 May; 307(2):H216-27. PMID: 24858849
We aimed to characterize early changes in microRNA expression in acute cardioprotection by ischemic pre- and postconditioning in rat hearts. Hearts isolated from male Wistar rats were subjected to 1)...
6.
Bencsik P, Paloczi J, Kocsis G, Pipis J, Belecz I, Varga Z, et al.
Pharmacol Res . 2014 Jan; 80:36-42. PMID: 24380772
Pharmacological inhibition of matrix metalloproteinase-2 (MMP-2) is a promising target for acute cardioprotection against ischemia/reperfusion injury. Therefore, here we investigated if the MMP inhibitor ilomastat administered either before ischemia or...
7.
Szucs G, Murlasits Z, Torok S, Kocsis G, Paloczi J, Gorbe A, et al.
Cardiovasc Drugs Ther . 2013 May; 27(4):269-77. PMID: 23673412
Purpose: Farnesol is a key metabolite of the mevalonate pathway and known as an antioxidant. We examined whether farnesol treatment protects the ischemic heart. Methods: Male Wistar rats were treated...
8.
Sarkozy M, Zvara A, Gyemant N, Fekete V, Kocsis G, Pipis J, et al.
Cardiovasc Diabetol . 2013 Jan; 12:16. PMID: 23320804
Background: Metabolic syndrome (coexisting visceral obesity, dyslipidemia, hyperglycemia, and hypertension) is a prominent risk factor for cardiovascular morbidity and mortality, however, its effect on cardiac gene expression pattern is unclear....
9.
Monostori P, Kocsis G, Okros Z, Bencsik P, Czetenyi O, Kiss Z, et al.
Clin Exp Nephrol . 2012 Dec; 17(4):569-74. PMID: 23224027
Background: The development of erythropoiesis-stimulating agents (ESAs) with extended serum half-lives has allowed marked prolongation of the administration intervals. The level of oxidative stress is increased in chronic kidney disease,...
10.
Kocsis G, Sarkozy M, Bencsik P, Pipicz M, Varga Z, Paloczi J, et al.
Am J Physiol Heart Circ Physiol . 2012 Sep; 303(10):H1229-36. PMID: 22982778
Metabolic diseases such as hyperlipidemia and diabetes attenuate the cardioprotective effect of ischemic preconditioning. In the present study, we examined whether another metabolic disease, prolonged uremia, affects ischemia/reperfusion injury and...